07:00 , Jul 30, 2012 |  BC Week In Review  |  Company News

ADMA management update

ADMA Biologics Inc. , Hackensack, N.J.   Business: Hematology, Infectious   Hired: James Mond as CMO and CSO, formerly EVP and CSO of Biosynexus Inc.  ...
07:00 , Mar 22, 2010 |  BC Week In Review  |  Clinical News

Pagibaximab regulatory update

The COMP issued a positive opinion to grant Orphan Drug designation to Biosynexus' pagibaximab to prevent sepsis caused by gram positive pathogens in premature infants <=34 weeks of gestational age. Pagibaximab is a humanized chimeric...
08:00 , Nov 5, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Sepsis Not applicable Studies in mice suggest that the bioactive lipid resolvin D2 (RvD2) could help reduce sepsis-related inflammation. In mouse models of microbial...
07:00 , Apr 2, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Sepsis Programmed cell death 1 (PDCD1; PD-1; CD279) Studies in mice and in vitro studies in murine macrophages suggest that...
07:00 , Sep 5, 2005 |  BC Week In Review  |  Company News

MedImmune Inc., GlaxoSmithKline deal

GSK granted MEDI worldwide rights to anti-staphylococcal monoclonal antibodies (MAbs), including BSYX-A110 , which is in Phase IIa testing to prevent serious bloodstream infections caused by staphylococcus in low-birth weight infants. MEDI is responsible for...
00:51 , Aug 30, 2005 |  BC Extra  |  Top Story

MedImmune, GSK antibody deal

GlaxoSmithKline (LSE:GSK; GSK) granted MEDI worldwide rights to anti-staphylococcal monoclonal antibodies (MAbs), including BSYX-A110 , which is in Phase IIa testing to prevent serious bloodstream infections caused by staphylococcus in low birth weight infants. MEDI...
07:00 , Jun 20, 2005 |  BC Week In Review  |  Company News

Biosynexus, QVT Fund LP deal

Biosynexus disclosed that it was acquired on May 26 by QVT Fund. Terms of the deal were not disclosed. Also, Biosynexus' BSYX-A110 has completed Phase II trials to prevent staphylococcal infection in premature infants. The...
07:00 , Jun 20, 2005 |  BC Week In Review  |  Company News

Biosynexus management update

Biosynexus Inc. , Gaithersburg, Md.   Business: Infectious   Hired: Irwin Scher as CEO, formerly VP of global clinical R&D at Merck KGaA ; he replaces Gerald Fischer, who resigned  ...
01:34 , Jun 15, 2005 |  BC Extra  |  Company News

Biosynexus acquired by QVT, names CEO

Biosynexus (Gaithersburg, Md.) disclosed that it was acquired on May 26 by QVT Fund. Terms of the deal were not disclosed. Also, Biosynexus hired Irwin Scher as CEO. Previously, Scher was VP of global clinical...
07:00 , Oct 20, 2003 |  BC Week In Review  |  Clinical News

BSYX-L210: Phase I/II

In a Phase I/II trial, BSYX-210 met safety and microbiological endpoints. Biosynexus Inc. , Gaithersburg, Md.   Product: BSYX-L210   Business: Infectious   Molecular target: NA   Description: Topical lysostaphin anti-staphylococcal cream   Standard Indication:...